SCHEMBL4010838

SCHEMBL4010838

Cc1ccccc1C(=O)N[C@H]1CCCN(c2ccccc2)C1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.63
RAB9A P51151 3/20 0.63
MEN1 O00255 2/20 0.58
KMT2A Q03164 2/20 0.58
CHRM1 P11229 4/20 0.56
POLB P06746 2/20 0.55
CNR1 P21554 1/20 0.55
CHRM2 P08172 1/20 0.54
CHRM5 P08912 1/20 0.54
SMN1; SMN2 Q16637 3/20 0.54
ALDH1A1 P00352 3/20 0.53
GAA P10253 2/20 0.52
MAPT P10636 2/20 0.52
MAPK1 P28482 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
GLA P06280 1/20 0.50
PPARD Q03181 1/20 0.49
PPARA Q07869 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4010842 1.00 NPC1 (0.63) NPC1RAB9AMEN1KMT2ACHRM1
SCHEMBL4009942 0.86 CNR1 (0.60) NPC1RAB9AMEN1KMT2ACHRM1
SCHEMBL4153507 0.86 CNR1 (0.60) NPC1RAB9AMEN1KMT2ACHRM1
SCHEMBL4011282 0.84 CNR1 (0.64) CNR1SMN1; SMN2ALDH1A1MAPK1PPARD
SCHEMBL4011287 0.84 CNR1 (0.64) CNR1SMN1; SMN2ALDH1A1MAPK1PPARD
SCHEMBL14859926 0.84 CNR1 (0.64) CNR1SMN1; SMN2ALDH1A1MAPK1PPARD
SCHEMBL13162925 0.80 MEN1 (0.71) NPC1RAB9AMEN1KMT2ACHRM1
SCHEMBL4004241 0.80 PPARA (0.52) RAB9ACNR1MAPK1PPARDPPARA
SCHEMBL4004234 0.80 PPARA (0.52) RAB9ACNR1MAPK1PPARDPPARA
SCHEMBL16334084 0.80 POLB (0.74) NPC1RAB9AMEN1KMT2ACHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1778229-A4 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORP (US) 2009-06-17 EP claimed
CN-101080226-A Amido compounds and their use as pharmaceuticals INCYTE CORP (US) 2007-11-28 CN claimed
EP-1778229-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2007-05-02 EP claimed
US-20060122197-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2006-06-08 US claimed
WO-2006020598-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2006-02-23 WO claimed
EP-1778229-A4 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORP (US) 2009-06-17 EP disclosed
CN-101080226-A Amido compounds and their use as pharmaceuticals INCYTE CORP (US) 2007-11-28 CN disclosed
EP-1778229-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2007-05-02 EP disclosed
US-20060122197-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2006-06-08 US disclosed
WO-2006020598-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122197-A1 Amido compounds and their use as pharmaceuticals HSD11B1, CYP11B1, HSD11B2 NPC1 325/4885RAB9A 1641/4885MEN1 379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.